Geode Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,144,217
| Closed | -$20.6M | – | 4229 |
|
|
2020
Q2 | $20.6M | Buy |
1,144,217
+44,807
| +4% | +$623K | ﹤0.01% | 1490 |
|
|
2020
Q1 | $7.84M | Buy |
1,099,410
+77,143
| +8% | +$963K | ﹤0.01% | 1886 |
|
|
2019
Q4 | $24.4M | Buy |
1,022,267
+77,159
| +8% | +$2.13M | 0.01% | 1431 |
|
|
2019
Q3 | $25.3M | Buy |
945,108
+73,683
| +8% | +$2.07M | 0.01% | 1319 |
|
|
2019
Q2 | $23.6M | Buy |
871,425
+65,666
| +8% | +$2.06M | 0.01% | 1367 |
|
|
2019
Q1 | $28M | Buy |
805,759
+75,510
| +10% | +$2.18M | 0.01% | 1189 |
|
|
2018
Q4 | $14.3M | Buy |
730,249
+33,734
| +5% | +$694K | ﹤0.01% | 1523 |
|
|
2018
Q3 | $18.5M | Buy |
696,515
+30,605
| +5% | +$999K | 0.01% | 1466 |
|
|
2018
Q2 | $25.2M | Buy |
665,910
+71,234
| +12% | +$2.72M | 0.01% | 1190 |
|
|
2018
Q1 | $19.4M | Sell |
594,676
-26,237
| -4% | -$1.15M | 0.01% | 1286 |
|
|
2017
Q4 | $30.2M | Buy |
620,913
+44,612
| +8% | +$2.26M | 0.01% | 973 |
|
|
2017
Q3 | $31.1M | Buy |
576,301
+87,623
| +18% | +$5.14M | 0.01% | 933 |
|
|
2017
Q2 | $27.4M | Buy |
488,678
+6,946
| +1% | +$278K | 0.01% | 978 |
|
|
2017
Q1 | $18.9M | Buy |
481,732
+41,524
| +9% | +$1.32M | 0.01% | 1194 |
|
|
2016
Q4 | $9.88M | Buy |
440,208
+27,207
| +7% | +$532K | ﹤0.01% | 1581 |
|
|
2016
Q3 | $9.38M | Sell |
413,001
-59
| -0% | -$1.39K | ﹤0.01% | 1543 |
|
|
2016
Q2 | $9.75M | Buy |
413,060
+14,181
| +4% | +$350K | 0.01% | 1446 |
|
|
2016
Q1 | $8.14K | Sell |
398,879
-4,597
| -1% | -$146K | ﹤0.01% | 1534 |
|
|
2015
Q4 | $20.8M | Buy |
403,476
+44,231
| +12% | +$2.14M | 0.01% | 871 |
|
|
2015
Q3 | $15.3M | Buy |
359,245
+6,597
| +2% | +$318K | 0.01% | 1048 |
|
|
2015
Q2 | $16.1M | Buy |
352,648
+11,256
| +3% | +$453K | 0.01% | 1079 |
|
|
2015
Q1 | $13M | Buy |
341,392
+37,016
| +12% | +$1.27M | 0.01% | 1190 |
|
|
2014
Q4 | $8.62M | Buy |
304,376
+38,611
| +15% | +$1.07M | 0.01% | 1448 |
|
|
2014
Q3 | $6.72M | Buy |
265,765
+185,921
| +233% | +$4.9M | ﹤0.01% | 1571 |
|
|
2014
Q2 | $2.33M | Buy |
79,844
+19,513
| +32% | +$472K | ﹤0.01% | 2281 |
|
|
2014
Q1 | $1.56M | Buy |
60,331
+12,884
| +27% | +$344K | ﹤0.01% | 2495 |
|
|
2013
Q4 | $1.22M | Buy |
47,447
+2,225
| +5% | +$54.1K | ﹤0.01% | 2590 |
|
|
2013
Q3 | $1.21M | Buy |
45,222
+26,458
| +141% | +$630K | ﹤0.01% | 2491 |
|
|
2013
Q2 | $461K | Buy |
+18,764
| New | +$373K | ﹤0.01% | 2919 |
|
Geode Capital Management's PTLA Position: Q3 2020 in Review
Geode Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,144,217 shares — an estimated $20.6M sold.
Geode Capital Management first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $31.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Geode Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Geode Capital Management sold 1,144,217 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $20.6M.
- Geode Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Geode Capital Management's Portola Pharmaceuticals, Inc. position peaked at $31.1M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Geode Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.